Cinnarizine/dimenhydrinate
Cinnarizine/dimenhydrinate, sold under the brand name Cizinate among others is a fixed-dose combination medication for the treatment of vertigo in adults.[1] It contains cinnarizine and dimenhydrinate.[1] It is taken by mouth.[1]
| Combination of | |
|---|---|
| Cinnarizine | Antihistamine and calcium channel blocker |
| Dimenhydrinate | Antihistamine and antiemetic |
| Clinical data | |
| Trade names | Cizigo, Cizinate, Cizere |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| UNII | |
It was approved for medical use in Australia in December 2018.[1]
References
- "Cizinate ARTG ID 288566". TGA eBS. Retrieved 23 July 2020.
Further reading
- Hahn A, Novotný M, Shotekov PM, Cirek Z, Bognar-Steinberg I, Baumann W (2011). "Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study". Clin Drug Investig. 31 (6): 371–83. doi:10.2165/11588920-000000000-00000. PMID 21401214.
- Scholtz AW, Ilgner J, Loader B, Pritschow BW, Weisshaar G (May 2016). "Cinnarizine and dimenhydrinate in the treatment of vertigo in medical practice". Wien. Klin. Wochenschr. 128 (9–10): 341–7. doi:10.1007/s00508-015-0905-5. PMC 4875047. PMID 26659910.
- Scholtz AW, Schwarz M, Baumann W, Kleinfeldt D, Scholtz HJ (June 2004). "Treatment of vertigo due to acute unilateral vestibular loss with a fixed combination of cinnarizine and dimenhydrinate: a double-blind, randomized, parallel-group clinical study". Clin Ther. 26 (6): 866–77. doi:10.1016/s0149-2918(04)90130-0. PMID 15262457.
External links
- "Cinnarizine". Drug Information Portal. U.S. National Library of Medicine.
- "Dimenhydrinate". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.